Ratings by Lucid Capital Markets (Dev Prasad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/20/2026 | Eloxx Pharma | ELOX | New Coverage | Buy (N/A) |
18.16 (15.01) |
-17.35% | Details | |
| 7/27/2026 | Polaryx Therapeutics | PLYX | New Coverage | Buy (N/A) |
2.05 (1.98) |
-3.41% | Details | |
| 5/4/2026 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
6.21 (6.51) |
4.83% | Details | |
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Palatin Technologies | PTN | New Coverage | Buy (N/A) |
19.63 (11.54) |
-41.21% | Details | |
| 11/5/2025 | Verrica Pharmaceuticals | VRCA | New Coverage | Buy (N/A) |
3.28 (5.24) |
59.76% | Details | |
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Neutral (Buy) |
6.03 (0.48) |
-92.04% | Details | |
| 8/25/2025 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
0.83 (28.44) |
3326.51% | Details | |
| 6/17/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
0.94 (3.83) |
307.45% | Details | |
| 5/23/2025 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
2.01 (4.78) |
137.81% | Details | |
| 3/18/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.50 (150.55) |
447.45% | Details | |
| 12/17/2024 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
9.42 (18.95) |
101.17% | Details | |
| 12/17/2024 | iBio, Inc. | IBIO | New Coverage | Buy (N/A) |
2.35 (1.26) |
-46.38% | Details | |
| 12/17/2024 | CalciMedica | CALC | New Coverage | Buy (N/A) |
2.81 (2.00) |
-28.83% | Details | |
| 11/19/2024 | Inflarx NV | IFRX | New Coverage | Buy (N/A) |
1.74 (2.16) |
24.14% | Details | |
| 11/19/2024 | aTyr Pharma | ATYR | New Coverage | Buy (N/A) |
3.01 (6.03) |
100.33% | Details |
